
| An All Natural Proteolytic Enzyme Formula specific acting to fibrin (a natural tPA inducer) ** |
A Brief Background:
BOLUOKE is activated only when fibrin is present (clot forming). In normal conditions it does not react with normal plasma proteins i.e. fibrinogen (precursor of fibrin) or prothrombin, therefore it does not cause prolonged bleeding which can be a side effect of other non-specific anti-clot treatments, or non steroid anti-inflammatory drugs (NSAID). i.e.. Heparin, warfarin, EDTA, aspirin, etc...It also does not produce some of the same dangers as with asprin which over long term use increases the risk of causing ulcers and blindness...
BOLUOKE's fibrinolytic function peaks in 5-30 minutes after the intake and returns to normal level in 90 minutes.
It is a much safer and effective preventative option to help those at high risk of stroke, heart attack, and deep vain thrombosis.**
Boluoke® (lumbrokinase) has been available to the North American health care professionals since November of 2001. It is a revolutionary product, and shows great promise in optimizing the fibrinolytic activity of the body with little side effects. Lumbrokinase is also referred to as earthworm fibrinolytic enzymes (EFE), earthworm powder enzymes (EPE), or e-PA.
For many centuries earthworm has been used in the Far East traditional medicine practice, and it was recorded in the "Ben Cao Gang Mu", the traditional Eastern world's pharmacopoeia, as a potent medicine for "Liver Wind uprising and Channel blockage" conditions.
"In the 1980's, Japanese scholoars like
Dr. Hisashi Mihara and Dr. Hiroyuki Sumi succeeded in extracting
a fibrin-dissolving enzyme from Lumbricus rubellus, and found
that this enzyme consists of a few proteolytic sub-enzymes, which
are collectively named Lumbrokinase."
Since then many Korean and Chinese researchers have compiled extensive scientific and clinical data on lumbrokinase extracted from Lumbricus rubellus and Eisenia fetida. In Japan and Korea lumbrokinase has been the main ingredient in "Dragon Heart", a popular health supplement for supporting circulatory health. Whereas in China, lumbrokinase has been studied thoroughly and has been used clinically for clot-induced hypoperfusion conditions since early 1990s.
Boluoke® (lumbrokinase) is the only fully
researched oral fibrinolytic supplement on the market. Besides
having in vitro studies, animal studies, toxicity studies, and
pharmacokinetic studies done, Boluoke® has also been put through
all phases of clinical trials (including randomized double blind
controlled studies) in China. Lumbrokinase has been studied as
a treatment for various clinical conditions, including ischemic
stroke, stable & unstable angina, acute myocardial infarction,
deep venous thrombosis, central retinal vein occlusion, diabetic
nephritis, fibrinogenemia, vascular
dementia,
Meniere's disease, and more.
All and all, Boluoke® seems to be beneficial for any illness that has an accompanying hypercoagulable blood state, which has been shown to be present in many chronic illnesses like fibromyalgia, chronic fatigue syndrome, autism, cancer, etc. Some practitioners are also recommending Boluoke® as a preventative measure for those who choose to be on hormone replacement therapy or birth control pills, those who have a history of heart attack or ischemic stroke or TIA, and and those, for one reason or another, could not tolerate prescription blood thinning agents.
|
**NOTE** Please consult your physician before taking this product or any other product if you are under the care of a physician, are pregnant, or have bleeding risks. People with known allergy to lumbrokinase should not take this product. KEEP OUT THE REACH OF CHILDREN.
|
PHYSICIANS NOTE: Medical monitoring of Hematocrit, platelet count, activated partial thromboplastin time, or prothrombin time is advised for at-risk individuals. Caution should be given to patients with active internal bleeding, ulcers, history of cerebrovascular accident, recent (within 2 months) intracranial or intraspinal surgery, intracranial neoplasm, arteriovenous malformation or aneurysm, known bleeding diathesis, and uncontrolled arterial hypertension. Although hemorrhagic strokes are far less common, (occur when an artery bursts), care should be given to differentiate the type and the cause of the strokes and the timing of using Bolouke. For example to use it after the hemorrhaging is over, and no further bleeding is anticipated. |
TERMINOLOGY DEFINITIONS:
Plasmin: The active portion of the fibrinolytic system, an enzyme with a high specificity for fibrin, with the particular ability to dissolve formed fibrin clots but also having a similar degradation effects on other plasma proteins and clotting factors and proteins in general.
Urokinase: A substance found in the urine of mammals, including human, and of other vertebrates, which activates the fibrinolytic system, used in hospital for the treatment of embolism. It decrease the levels of fibrinogen and plasminogen and an increase in the amount of circulating fibrin may persist for 12-24 hours.
t-PA: Tissue
Plasminogen Activator (the body's own natural method of dissolving
excess clot factors)
60 Capsules $95.00 + S & H or 3 bottles
for $265.00 (an initial course of therapy requires 3 bottles)
![]()